A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Study Details
Study Description
Brief Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor under domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit kinase. In the Phase III study, patients who failed at least two systemic chemotherapy (third-line or above) or were intolerant of the drugs were treated with anlotinib or placebo. The PFS and OS in the anlotinib group were 5.37 months and 9.63 months, respectively. The placebo group PFS and OS were 1.4 months and 6.3 months. Therefore, it is envisaged to use anlotinib combined with docetaxel to treat wild-type advanced non-squamous non small cell lung cancer to further improve the patient's PFS or OS.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a single arm clinical trial conducted in China. The purpose of this study is to assess the efficacy and safety of Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) combined with Docetaxel (75mg/m2 IV d1) in the treatment of wild-type advanced non-squamous non small cell lung cancer patients with progression after immunotherapy plus chemotherapy as first-line treatment. After being informed about the study and potential risks, all patients giving written informed consent will undergo a 4-week screening period to determine eligibility for study entry. The expected sample size is 42.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Anlotinib hydrochloride plus Docetaxel Paticipants receive 4 to 6 cycles (21 days per cycle) combined administration period of Anlotinib Hydrochloride and Docetaxel, and then Anlotinib Hydrochloride maintenance treatment. |
Drug: Anlotinib Hydrochloride plus Docetaxel
Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)
|
Outcome Measures
Primary Outcome Measures
- Progress free survival (PFS) [each 42 days up to PD or death (up to 24 months)]
PFS is defined as the time from the date of enrollment to the first occurrence of disease progression or death due to any cause
Secondary Outcome Measures
- Objective Response Rate (ORR) [each 42 days up to intolerance the toxicity or PD (up to 24 months)]
ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.prior to progression or any further therapy.
- Disease Control Rate (DCR) [each 42 days up to intolerance the toxicity or PD (up to 24 months)]
DCR is defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.
- Overall Survival (OS) [From randomization until death (up to 24 months)]
OS is defined as the time from the date of enrollment to the date of death due to any cause.
- Quality of Life score (QoL) [each 42 days up to intolerance the toxicity or PD (up to 24 months)]
use EORTC QLQ-C30(version 3) questionnaire to evaluate the quality of life.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The subjects voluntarily join the study and sign an informed consent form, with good compliance and cooperation with follow-up.
-
EGFR、ALK mutation-negative；Patients have progressed after receiving immunotherapy combined with platinum-based chemotherapy and have not used docetaxel. (Recurrent patients have previously received adjuvant chemotherapy and relapsed within six months.)
-
≥ 18 and ≤ 75 years of age; female or male.
-
Diagnosed with local advanced and/or metastatic NSCLC (phase IIIB、IIIC or IV) through Histology or cytology (using the new version of staging announced by the American Joint Committee on Cancer on January 1, 2018), or recurrent non- squamous non-small cell lung cancer.
-
There is at least one target lesion that has not received radiotherapy，and in at least one direction (the maximum diameter needs to be recorded)≥10 mm; the shortest diameter of the lymph node ≥15mm.
-
Expected Survival Time: at least 3 months
-
ECOG PS：0-1
-
The damage caused by prior treatment has been recovered (NCI-CTCAE 4.0 version classification≤level 1)；Receiving cytotoxic drugs, bevacizumab (Avastin),endostar, surgery ≥ 3 weeks；Radiotherapy (except local palliative radiotherapy) ≥ 2 weeks.
-
The main organs function are normally, the following criteria are met
-
Blood routine examination criteria should be met (no blood transfusion and blood products within 14 days): HB≥90 g/L; ANC ≥ 1.5×109/L; PLT≥80×109/L;
-
Biochemical examinations must meet the following criteria: TBIL<1.5×ULN; ALT and AST < 2.5×ULN, and for patients with liver metastases < 5×ULN; Serum Cr≤ 1.25×ULN or endogenous creatinine clearance > 45ml/min (Cockcroft-Gault formula);
- Women of childbearing potential must have taken reliable contraceptive measures or the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment, and willing to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after the last test drug administration. Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after the last test drug administration or surgical sterilization.
Exclusion Criteria:
-
Squamous carcinoma of lung (including Adenosquamous carcinoma); Small cell lung cancer (including lung cancer mixed with small cell lung cancer and non- small cell lung cancer);
-
Previously used Anlotinib Hydrochloride, Docetaxel, Paclitaxel; Postoperative adjuvant treatment of taxanes is acceptable;
-
Imaging (CT or MRI) shows that the distance between tumor lesion and the large blood vessel is ≤ 5 mm, or there is a central tumor that invades the local large blood vessel; or there is a significant pulmonary cavity or necrotizing tumor;
-
Medical history and combined history：
-
Significant brain metastases, cancerous meningitis, spinal cord compression, or imaging CT or MRI screening for brain or pia mater disease (a patient with brain metastases who have completed treatment and stable symptoms in 28 days before enrollment may be enrolled, but should be confirmed by brain MRI, CT or venography evaluation as no cerebral hemorrhage symptoms);
-
The patient is participating in other clinical studies;
-
Other active malignancies that require simultaneous treatment;
-
Patients with a history of malignant tumors except for patients with cutaneous basal cell carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or orthotopic cervical cancer who have undergone a possible curative treatment and have no disease recurrence within 5 years from the start of treatment;
-
Patients with previously systemic anti-tumor treatment-related adverse reactions (excluding hair loss) who have not recovered to NCI-CTCAE ≤level 1;
-
Abnormal blood coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolytic or anticoagulant therapy; Note: Under the premise of prothrombin time international normalized ratio (INR) ≤ 1.5, low-dose heparin (adult daily dose of 0.6 million to 12,000 U) or low-dose aspirin (daily dosage ≤ 100 mg) is allowed for preventive purposes;
-
Renal insufficiency: urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0g;
-
The effects of surgery or trauma have been eliminated for less than 14 days before enrollment in subjects who have undergone major surgery or have severe trauma;
-
Severe acute or chronic infections requiring systemic treatment;
-
Suffering from severe cardiovascular disease: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms); according to NYHA criteria, grades III to IV Insufficient function, or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) <50%;
-
Peripheral neuropathy with ≥CTCAE degree 2 currently exists, except for trauma caused;
-
Respiratory syndrome (≥CTC AE grade 2 dyspnea), serous effusion (including pleural effusion, ascites, pericardial effusion) requiring treatment;
-
Long-term unhealed wounds or fractures;
-
Decompensated diabetes or other ailments treated with high doses of glucocorticoids;
-
Factors that have a significant impact on oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction;
-
Clinically significant hemoptysis (daily hemoptysis greater than 50ml) within 3 months before enrollment; or significant clinically bleeding symptoms or defined bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood ++ and above, or suffering from vasculitis;
-
Events of arterious/venous thrombosis occurring within 12 months prior to enrollment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;
-
Planned for systemic anti-tumor therapy, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (Or use mitomycin C within 6 weeks prior to receiving the test drug). Extended-field radiotherapy (EF-RT) was performed within 3 weeks before grouping or limited-field radiotherapy to be evaluated for tumor lesions within 2 weeks before grouping;
-
Uncontrollable hypertension with two or more combined treatments (systolic blood pressure ≥145 mmHg or diastolic blood pressure ≥90 mmHg);
-
Have a history of psychotropic substance abuse and are unable to quit or have a mental disorder;
- Physical examination and laboratory examination findings
-
A known history of HIV testing positive or acquired immunodeficiency syndrome (AIDS);
-
untreated active hepatitis (hepatitis b: HBsAg positive and HBV DNA ≥500 IU/ml; Hepatitis c: HCV RNA is positive and liver function is abnormal); Combined with hepatitis b and hepatitis c infection;
- Other factors that may cause the study to be terminated midway according to the researchers' judgment, such as other serious diseases or severe laboratory test abnormalities or factors that will endanger patients' safety, or family or society factors of test data and sample collection.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shandong Cancer Hospital | Jinan | Shandong | China |
Sponsors and Collaborators
- Shandong Cancer Hospital and Institute
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209.
- Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. Epub 2014 Jun 2.
- Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000 May;18(10):2095-103.
- SDZLEC2020-037-01